This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis

This is an early-phase safety study of a treatment called GC012F — a type of CAR T-cell therapy — for people with multiple sclerosis (MS). CAR T-cells are immune cells that have been genetically modified to target and remove overactive immune cells that are attacking the nervous system in MS. This is a first-in-human study focused primarily on safety. **You may be eligible if...** - You have been diagnosed with multiple sclerosis - Your blood counts (white blood cells, red blood cells, and platelets) meet specific minimum levels - Your immune protein (IgG) levels are sufficient - You are in good enough health to undergo this experimental treatment **You may NOT be eligible if...** - Your blood counts are too low - You have active serious infections - You are pregnant or breastfeeding - You have other significant health conditions that would make this treatment unsafe Talk to your doctor to see if this trial is right for you.